ASTONEA LABS LIMITED

Our Company was originally incorporated as "AHU Laboratories Private Limited". as a private limited comp any, under the provisions of the Companies Act, 2013 pursuant to certificate of incorporation dated April 11,2017. Our Company changed its name from "AHU Laboratories Private Limited" to "Astonea Labs Private Limited" pursuant to Rule29of the Companies (Incorporation) Rules, 2014 vide certificate of incorporation dated February 26,2019. Subsequently, our Company converted into "Astonea Labs Limited", a public limited company vide fresh certificate of incorporation dated January 11,2024the Corporate Identification Number of our Company is U24304CH2017PLC041482

Our Company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products. These include antibiotic drugs, anti-cold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynecological concerns, analgesics, fungal infections, and multivitamins. We also offer products for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums. All our products adhere to the rigorous standards of the pharmaceutical and cosmetics industries. Additionally, we are involved in the trading of certain packing materials and raw materials used in pharmaceutical and cosmetic products. We are engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally.

• Our Company has not satisfied the annual OMFUA, under which the FDA assesses and collects fees from qualifying manufacturers of OTC monograph drugs which is mandatory to be paid by all the manufacturers of OTC drugs.

• There have been some instances of delayed and non-filings in the past with the Registrar of Companies which may attract penalties.

• We are dependent on third parties for the supply of raw materials and such third parties could fail in meeting their obligations, which may have a material adverse effect on our business, results of operations and financial condition. Further our 35.47%, 41.96%, 55.74% and 33.90% of our total purchases are derived from our top 10 suppliers for Financial Years ended on March 31, 2024, March 31,2023, March 31,2022 and for the period ended December 31,2024 respectively.

• Our Company, its Promoters, Directors, and Group Companies are party to certain legal proceedings. Any adverse outcome in such proceedings may have an adverse impact on our reputation, business, financial condition, results of operations, and cash flows.

• Our business is significantly dependent on the revenue generated by manufacturing and selling the pharmaceuticals, which constitutes a substantial portion of our sales and such dependence exposes us to various risks that could materially affect our business operations, financial condition, and results of operations.

• We have had negative cash flows in the past. Sustained negative cash flow could adversely impact our business, financial condition, and results of operations.

• Major revenue of our Company is generated from contract manufacturing and any adverse factors affecting the outsourcing of manufacturing by our customers could have an adverse on our business, results of operations and financial condition.

• One of our domain names is registered under the name Astonea Foundation. Any dispute with the Astonea Foundation or other unforeseen circumstance may lead to loss of our online presence which could adversely affect our business.

• We do not have any long-term contracts with our suppliers. Any shortfall in the supply of our raw materials or an increase in our raw material costs, or other input costs, may adversely affect the pricing and supply of our products and have an adverse effect on our business, results of operations and financial condition.

• We have certain contingent liabilities which if materialized, could adversely affect our financial condition.

• The auditor's report on the Restated Financial Statements highlights certain matters relating to the Companies (Auditors' Report) Order, 2020.

• The Merchant Banker associated with the Issue has handled 3 Public Issue in the past 3 financial years, out of which nil Issue closed below Issue Price on listing date.

• The average cost of acquisition of Equity Shares by the Individual Promoter is:

• P/E ratio based on the Basic and Diluted EPS, as restated for Financial Year 2023-24 for the Company is 26.95 at cap price.

• Weighted Average Return on Net worth for Financial Year 2023-24,2022-23 and 2021 -22 is 19.18%.

• The weighted average cost of acquisition of all Equity Shares transacted in last 18 months from the date of Prospectus is as given below:

• Weighted average cost of acquisition compared to Floor price and Cap Price:

NA = Not Applicable

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBIICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-lnstitutional Bidders and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" on page 293 of the Prospectus.

The Company received 4 Anchor Investor Application Forms from 4 Anchor Investors (including Nil mutual funds through Nil Mutual Fund schemes) for 8,65,000 Equity Shares. Such 4 Anchor Investors through 4 Anchor Investor Application Forms were allocated 7,90,000 Equity Shares at a price of Fts.135/- per Equity Share under the Anchor Investor Portion, aggregating to Rs. 10,66,50,000/-

The issue was subscribed to the extent of 2.15 times (including the Anchor Investor Portion) as per the bid books of BSE (the "Bid Files") after removing multiple and duplicate bids & Bid not bank cases. The Details of the Applications received from various categories (before technical rejection) are as under:

Detail of the Applications Received:

* This excludes 26 applications for 26,000 Equity Shares aggregating to Rs. 35,10,000 from Retail Individual which were not in bid book but which were banked.

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange-BSE on May 30,2025

1) Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Retail Individual Investors, who have bid at cut-off Price or at or above the Issue Price of Rs135.00 per equity shares, was finalized in consultation with BSE. The category was subscribed to the extent of 1.64078 times i.e. for 15,21,000 Equity Shares. Total number of shares allotted in this category is 9,27,000 Equity Shares to 927 successful applicants. The category wise details of the Basis of Allotment are as under:

2) Allocation to Non-lnstitutional Investors (After Technical Rejections): The Basis of Allotment to the Non-lnstitutional Investors, who have bid at cut-off Price or at or above the Issue Price of Rs135.00 per equity shares, was finalized in consultation with BSE. The category was subscribed to the extent of 5.59398 times i.e. for 22,32,000 Equity Shares. Total number of shares allotted in this category is 3,99,000 Equity Shares to 42 successful applicants. The category wise details of the Basis of Allotment are as under:

Please Note: 1 Additional lot of 1000 shares have been allocated to Categories 8000,10000,15000 in the ratio of 1:2,2:3 & 1:2

3) Allocation to QIBs excluding Anchor Investors (After Technical Rejections): The Basis of Allotment to the QIBs excluding Anchor Investors, who have bid at cut-off Price or at or above the Issue Price of Rs135.00 per equity shares, was finalized in consultation with BSE. The category was subscribed to the extent of 1.74906 times i.e. for 9,27,000 Equity Shares. Total number of shares allotted in this category is 5,30,000 Equity Shares to 4 successful applicants. The category wise details of the Basis of Allotment are as under:

4) Allocation to Anchor Investors (After Technical Rejections & Withdrawal): The Company in consultation with the BRLM has allotted 7,90,000 Equity Shares to 4 Anchor Investors at Anchor Investor Issue Price of Rs135 per equity shares in accordance with the SEBIICDR Regulations. The category wise details of the Basis of Allotment are as under:

The Basis of Allotment to Market Maker, who have bid at Issue Price of Rs135.00 per equity shares or above, was finalized in consultation with BSE, The category was subscribed by 1.00 time i.e. for 1,44,000 shares the total number of shares allotted in this category is 1,44,000 Equity Shares. The category wise details of the Basis of Allotment are as under:

The Board of Directors of the Company at its meeting held on May 30,2025 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for issue of the Equity Shares to various successful applicants. The CAN-cum-allotment advices and/or notices will forward to the email id's and address of the Applicants as registered with the depositories / as filled in the application form on or before June 02,2025. Further, the instructions to Self Certified Syndicate Banks for unblocking the amount will process on or prior to June 02,2025. In case the same is not received within ten days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the SME platform of BSE Ltd within three working days from the date of the closure of the issue. Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated May 30,2025 ("Prospectus") filed with Registrar of Companies, Chandigarh.

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFin Technologies Limited at www.kfintech.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, PAN, Client ID, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

	Kfin Technologies Limited
	Address: Selenium Tower B, Plot No-31 & 32, Financial District, Nanakramguda, Serilingampally Hyderabad Rangareddi TG 500032
	Tel No.: +91-40-67162222/18003094001
	Fax No. +91-40-6716 1563
	E-mail: astonea.ipo@kfintech.com
	Investor Grievance Email: einward.ris@kfintech.com
	Website: www.kfintech.com
	Contact Person: Mr. M. Murli Krishna
	SEBI Registration No: INR000000221

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHERTHE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF ASTONEA LABS LIMITED.

Disclaimer: Astonea Labs Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Prospectus dated May 30,2025 has been filed with the Registrar of Companies, Chandigarh, Punjab and there after with SEBI and the Stock Exchange. The Prospectus is available on the website of BSE atwwv.bseindia.com and is available on the website of the BRLM at wwv.oneviewadvisors.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the section titled "Risk Factors" beginning on page 30 of the Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state secures laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.